In substance use disorder, dopamine is released within the reward center of the brain. Where is this located?
The ventral tegmental area and the nucleus accumbens
The mesocortical pathway
The locus coeruleus
The raphe nucleus
The Correct Answer is A
Choice A reason: The ventral tegmental area (VTA) and nucleus accumbens are central components of the mesolimbic dopamine pathway, which is the primary reward circuit in the brain. Dopamine release in this pathway reinforces behaviors and is heavily involved in addiction and substance use disorders.
Choice B reason: The mesocortical pathway connects the VTA to the prefrontal cortex and is involved in cognition, emotion, and executive function. While it plays a role in psychiatric conditions, it is not the primary reward center.
Choice C reason: The locus coeruleus is involved in arousal and stress responses via norepinephrine, not dopamine. It is not part of the reward system central to substance use disorders.
Choice D reason: The raphe nucleus is the primary source of serotonin in the brain and is involved in mood regulation. It does not mediate dopamine-driven reward processes.
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is A
Explanation
Choice A reason: Lorazepam is preferred in patients with hepatic impairment because it is metabolized through conjugation rather than oxidation. This makes it safer and more predictable in individuals with liver dysfunction. It is effective in managing alcohol withdrawal symptoms without accumulating toxic metabolites.
Choice B reason: Chlordiazepoxide is metabolized hepatically and has a long half-life. In patients with liver disease, it can accumulate and increase the risk of sedation and toxicity. It is generally avoided in hepatic impairment.
Choice C reason: Clonazepam is also metabolized by the liver and has a long half-life. It is not typically used for alcohol withdrawal and poses risks in hepatic disease.
Choice D reason: Diazepam is highly lipophilic and extensively metabolized by the liver. It has active metabolites that can accumulate in hepatic dysfunction, increasing the risk of oversedation and respiratory depression. It is not recommended in this context.
Correct Answer is C
Explanation
Choice A reason: Prazosin is an alpha-1 adrenergic antagonist commonly used to treat PTSD-related nightmares. It does not have significant CNS depressant effects and does not interact dangerously with buprenorphine. Therefore, it can be continued during induction.
Choice B reason: Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used for anxiety and depression. It does not pose a significant risk when combined with buprenorphine and is generally safe to continue during induction.
Choice C reason: Alprazolam is a benzodiazepine with potent CNS depressant effects. When combined with buprenorphine, it increases the risk of respiratory depression, sedation, and overdose. Discontinuation or tapering is recommended prior to buprenorphine induction to reduce these risks.
Choice D reason: This option implies that no medications need to be discontinued, which is incorrect. Alprazolam poses a significant safety concern and should be reconsidered before initiating buprenorphine.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.
